Can Tenofovir diphosphate be a candidate drug for Sars-Cov2? First
clinical perspective
Abstract
COVID-19 pandemic continues to spread across the world in late September
2020. To date, total cases of COVID-19 exceed 33 million including
996.342 deaths according to the WHO data. Although hydroxychloroquine,
oseltamivir, remdesivir, favipiravir have been reported as an
anti-SARS-CoV-2 effect, it is still unclear the fully effective
protective drug and treatment. Herein, we report a woman under Tenofovir
diphosphate who live and close contact with his COVID-19 positive
husband. Although she had close contact with his husband without measure
in the home she did not show any symptoms and signs of COVID-19 and her
PCR test along with antibody test negative. Given the high reproduction
number of SARS-CoV-2 and long-term close contact of the case, it can be
speculated that Tenofovir could interfere with the transmission of
COVID-19.29 Sep 2020Submitted to International Journal of Clinical Practice 30 Sep 2020Submission Checks Completed
30 Sep 2020Assigned to Editor
04 Oct 2020Reviewer(s) Assigned
05 Oct 2020Review(s) Completed, Editorial Evaluation Pending
21 Oct 2020Editorial Decision: Accept
Jan 2021Published in International Journal of Clinical Practice volume 75 issue 1. 10.1111/ijcp.13792